article Open access

STL127705 synergize with olaparib in castration-resistant prostate cancer by inhibiting homologous recombination and non-homologous end-joining repair.

Peng Sun^a, Wenyang Zhao^a, Haibin Li^a, Yigeng Feng^a, Lei Chen^a, Hongwen Cao^a

^aSurgical Department I (Urology Department), Longhua Hospital Shanghai University of Traditional Chinese Medicine No. 725 Wanping Road South, Xuhui District, Shanghai 200032, China

PubMedNational Institutes of Health2023-01-01 4 citations31 references

Looking for the full paper…

Export

Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.

Abstract

study demonstrated that the combination of STL127705, olaparib, and enzalutamide exhibited a significant anti-tumor effect. STL127705 combined with olaparib have a potential therapeutic effect on castration-resistant prostate cancer through inhibiting homologous recombination and non-homologous end-joining repair.

Plain-language summary

AI illustration of the topic of “STL127705 synergize with olaparib in castration-resistant prostate cancer by inhibiting homologous recombination and non-homologous end-joining repair.”

STL127705 synergize with olaparib in castration-resistant prostate cancer by inhibiting homologous recombination and non-homologous end-joining repair.

Abstract

Plain-language summary

Discussion